EGFR and adenocarcinoma: Although the EGFR mutatedsquamous lung cancer patients can be treated with EGFR-TKIs as well, the mutationrate in this population is much lower than that in the non-squamous subtypes (around10% in Caucasian adenocarcinoma patients, 30% in Asian adenocarcinoma patients, butonly around 3% in squamous patients [10]).